AG
RDY icon

Aperio Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Aperio Group’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$46.3M Sell
3,249,795
-326,480
-9% -$4.4M 0.14% 141
2020
Q3 		$49.8M Sell
3,576,275
-214,995
-6% -$2.56M 0.17% 112
2020
Q2 		$40.2M Sell
3,791,270
-302,295
-7% -$3.08M 0.15% 132
2020
Q1 		$33M Buy
4,093,565
+374,710
+10% +$3.12M 0.15% 147
2019
Q4 		$30.2M Buy
3,718,855
+733,150
+25% +$5.79M 0.11% 204
2019
Q3 		$22.6M Buy
2,985,705
+477,385
+19% +$3.55M 0.09% 264
2019
Q2 		$18.8M Buy
2,508,320
+541,420
+28% +$4.26M 0.08% 296
2019
Q1 		$15.9M Buy
1,966,900
+429,150
+28% +$3.26M 0.07% 320
2018
Q4 		$11.6M Buy
1,537,750
+356,160
+30% +$2.5M 0.06% 360
2018
Q3 		$8.18M Buy
1,181,590
+128,365
+12% +$858K 0.04% 509
2018
Q2 		$6.78M Buy
1,053,225
+224,405
+27% +$1.42M 0.03% 563
2018
Q1 		$5.42M Sell
828,820
-94,810
-10% -$664K 0.03% 622
2017
Q4 		$6.94M Buy
923,630
+13,760
+2% +$99.1K 0.04% 525
2017
Q3 		$6.49M Buy
909,870
+92,295
+11% +$664K 0.04% 514
2017
Q2 		$6.89M Buy
817,575
+83,670
+11% +$680K 0.04% 484
2017
Q1 		$5.89M Buy
733,905
+69,855
+11% +$603K 0.04% 489
2016
Q4 		$6.01M Sell
664,050
-113,540
-15% -$1.06M 0.05% 442
2016
Q3 		$7.22M Sell
777,590
-6,255
-0.8% -$59.7K 0.05% 418
2016
Q2 		$8.03M Buy
783,845
+32,665
+4% +$299K 0.06% 351
2016
Q1 		$6.79M Buy
751,180
+113,640
+18% +$1.02M 0.06% 381
2015
Q4 		$5.9M Sell
637,540
-149,955
-19% -$1.64M 0.05% 404
2015
Q3 		$10.1M Buy
787,495
+63,525
+9% +$789K 0.1% 232
2015
Q2 		$8.01M Buy
723,970
+57,240
+9% +$632K 0.08% 291
2015
Q1 		$7.61M Buy
666,730
+42,080
+7% +$446K 0.09% 295
2014
Q4 		$6.3M Buy
624,650
+13,540
+2% +$143K 0.08% 315
2014
Q3 		$6.42M Buy
611,110
+6,125
+1% +$57.6K 0.09% 286
2014
Q2 		$5.22M Sell
604,985
-14,270
-2% -$120K 0.08% 320
2014
Q1 		$5.44M Buy
+619,255
New +$5.39M 0.08% 331
2013
Q4 		– Sell
-479,215
Closed -$3.79M – 341
2013
Q3 		$3.62M Buy
479,215
+22,815
+5% +$166K 0.07% 367
2013
Q2 		$3.45M Buy
+456,400
New +$3.33M 0.08% 305

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Aperio Group's RDY Position: Q4 2020 in Review

Aperio Group reduced its Dr. Reddy's Laboratories (RDY) stake by 9.1% in Q4 2020, selling an estimated $4.4M and leaving 3,249,795 shares worth $46.3M. The position accounts for 0.14% of the portfolio, ranked #141.

Aperio Group first reported a position in RDY in Q2 2013 and has held it in 30 quarters since. The position peaked at $49.8M in Q3 2020. 174 funds tracked by Wall St. Rank hold RDY as of Q4 2020.

  • Aperio Group held 3,249,795 shares of Dr. Reddy's Laboratories worth $46.3M as of Q4 2020.
  • Aperio Group sold 326,480 Dr. Reddy's Laboratories shares in Q4 2020, an estimated $4.4M.
  • Dr. Reddy's Laboratories made up 0.14% of Aperio Group's portfolio in Q4 2020, its #141 holding.
  • Aperio Group first reported a position in Dr. Reddy's Laboratories in Q2 2013 and has held it in 30 quarters since.
  • Aperio Group's Dr. Reddy's Laboratories position peaked at $49.8M in Q3 2020.
  • 174 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.